SCHEMBL26192829

SCHEMBL26192829

O=[N+]([O-])c1cc(-c2ccccc2)cc(-c2cc[nH]n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.48
▸ LMNA P02545 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ HPGD P15428 1/20 0.46
▸ IDO1 P14902 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ CYP19A1 P11511 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ CRHBP P24387 1/20 0.41
▸ CRHR2 Q13324 1/20 0.41
▸ NPBWR1 P48145 1/20 0.40
▸ ALOX5 P09917 1/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27708602 0.88 CYP19A1 (0.52) MAPTLMNAMEN1KMT2AHPGD
SCHEMBL1852084 0.83 IDO1 (0.61) MAPTLMNAMEN1KMT2AIDO1
SCHEMBL13827223 0.80 CYP19A1 (0.65) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL2138930 0.77 CYP19A1 (0.73) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL3014712 0.76 MAPT (0.49) MAPTLMNAMEN1KMT2ASMN1; SMN2
SCHEMBL29484275 0.76 GP6 (0.46) NPC1RAB9A
SCHEMBL17900086 0.76 GP6 (0.46) NPC1RAB9A
SCHEMBL25300036 0.74 TDP1 (0.45) MAPTMEN1KMT2AHPGDSMN1; SMN2
SCHEMBL20073282 0.74 GP6 (0.44) MEN1KMT2AIDO1NPC1RAB9A
SCHEMBL15860824 0.74 GP6 (0.44) MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 — — US disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 — — US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 — — US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 MAPT 2994/4885LMNA 2104/4885MEN1 4404/4885
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 MAPT 2994/4885LMNA 2104/4885MEN1 4404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback